Analyzing the Future of Peanut Allergy Treatment Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the peanut allergy treatment market grown over the years?
In recent times, the market size of peanut allergy treatment has witnessed fast-paced growth. There’s an expected increase from a size of $0.45 billion in 2024 to $0.51 billion in 2025 with a compound annual growth rate (CAGR) of 11.4%. This surge during the historical period is due to several factors such as rising incidence, progression in diagnostic tests, augmented public consciousness and worry, establishment of early intervention methods, and the official permission for peanut allergy therapeutic measures.
What Is the forecasted market size and growth rate for the peanut allergy treatment market?
The market for peanut allergy treatment is projected to witness expeditious growth in the approaching years, expanding to $0.77 billion in 2029 with a compound annual growth rate (CAGR) of 11.1%. This projected growth during the forecasted period can be linked to the consistently rising prevalence of the allergy, advancements in personalized medicine, the emergence of innovative immunotherapeutic solutions, increased financial backing from public and private sectors, and development in telemedicine services. Key trends expected during the same period include the growing acceptance of immunotherapy, progress in biologic treatments, adoption of probiotics-based therapies, technological upgrades in treatment delivery systems, personalized medicinal strategies, and endorsement and assistance from regulatory bodies.
Get your peanut allergy treatment market report here!
https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report
What are the major factors driving growth in the peanut allergy treatment market?
The emergence and progression of the peanut allergy treatment market are predicted to be fueled by investments in allergy treatment research and development. The financial commitment dedicated to innovation, product enhancement, and technology improvement by firms, entities, or governments is known as research and development (R&D) investment. The capital invested in allergy treatment research and development plays a crucial part in progress of peanut allergy treatments, facilitating the formation of novel immunotherapies and desensitization methods. These aim to mitigate allergic symptoms and enhance life quality for patients with peanut allergies. For example, the Victorian Government disclosed a strategic investment of $12 million in Aravax, an Australian clinical-stage biotech firm, in January 2024, in order to substantially push forward worldwide peanut allergy treatment. This capital contributes to a larger $66 million funding round intended to develop Aravax’s unique immunotherapy, PVX108. This endeavor has gained approval for Phase 2 trials from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), highlighting its potential to influence global public health. As such, the expenditure on allergy treatment research and development is the driving force behind the peanut allergy treatment market’s expansion.
What key areas define the segmentation of the global peanut allergy treatment Market?
The peanut allergy treatment market covered in this report is segmented –
1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Subsegments:
1) By Antihistamines: Oral Antihistamines, Topical Antihistamines
2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)
3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers
4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp
What are the top market players propelling the growth of the peanut allergy treatment industry?
Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd., Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.
How are evolving market trends shaping peanut allergy treatment Strategies?
The focus of primary players in the peanut allergy treatment market is centering around the creation of biologic therapies like anti-IgE monoclonal antibodies. Their goal is to propose highly specific and effective treatments for peanut allergy control, with the aim of enhancing patient results and their lives. Anti-IgE monoclonal antibodies serve as a form of therapeutic agent specifically drawn up to identify and neutralize immunoglobulin E (IgE) antibodies present within the body. For instance, a pharmaceutical enterprise based in Switzerland, Novartis Pharmaceuticals Corporation, gained approval from the Food and Drug Administration (FDA) for the drug Xolair (omalizumab) in February 2024. This medicine aims to decrease allergic reactions, encompassing anaphylaxis, in patients aged 1 and above suffering from IgE-mediated food allergies. The approval was granted on the back of data gathered from the NIH-backed Phase III OUtMATCH study, evidencing a significant upsurge in food allergy tolerance in patients treated with Xolair compared to those on a placebo.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15888
What regions are dominating the peanut allergy treatment market growth?
North America was the largest region in the peanut allergy treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Keloids Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report
Neuralgia Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report
Merkel Cell Carcinoma Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
